Call picture

Research call on drug resistance now open

The transnational project call Disrupting drug resistance using innovative design is now open. The call involves 27 funding organisations from 18 countries and the total estimated call budget is about 19 million Euro.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

The call will follow a two-step evaluation procedure and the deadline for pre-proposals is 8 March 2022.

Read more on the Disrupting drug resistance using innovative design call page.

Transmission dynamics 2016 call picture

Main achievements of the AMR Transmission Dynamics call

The outputs, outcomes and the impact generated by the projects supported under the 2016 JPIAMR joint co-funded call “AMR Transmission Dynamics have now been published in a report. The report highlights the effect of supporting excellent science through transnational research collaborations.

Numerous peer-reviewed scientific articles in highly recognised journals have been published by the supported projects on the research findings, and a patent has been filed on a new peptide molecule discovered in one of the projects.

Other impact highlights are:

  • New knowledge generation to address AMR at regional, national and global scale with a One Health approach.
  • Science-based policy and societal impact.
  • Innovative tools and analytical methods and technologies.
  • Interdisciplinary expertise in transnational collaboration.

Download the report (pdf 1 MB): 2016 call on AMR Transmission Dynamics: Research outputs, outcome and impact of the projects

AMR Transmission Dynamics call

The third JPIAMR joint co-funded call “AMR Transmission Dynamics” was launched in 2016. The call was conducted by 21 participating funding organisations from 18 countries and was co-funded by the European Commission (EC) within the JPI-EC-AMR ERA-Net co-fund grant . The call resulted in the awarding of 29.1 million euros (M EUR) including a 6.3 M EUR contribution from the EC to 19 research projects. The 19 project consortia included a total of 118 researchers from 16 countries aiming to bridge the knowledge gap on AMR transmission mechanisms.

The call was one of the first of its kind to address transmission of antibiotic resistance following a One Health approach not only focussing the European and North American countries but also including research activities in the low- and middle-income countries (LMIC).

JPIAMR celebrating 10 years

JPIAMR celebrating 10 years of achievements

It is with great pleasure that we acknowledge that JPIAMR officially celebrates ten years as an international collaborative platform. From its inception in December 2011 until today, JPIAMR has achieved and exceeded its mission to coordinate national funding of antimicrobial resistance (AMR) research, guided by a shared strategic research and innovation agenda. Today 28 countries fund AMR research with a One Health approach, as members of JPIAMR. More than 1 400 researchers in 71 countries have been engaged in research that has been funded by JPIAMR members. In total, 125 million Euros have been allocated to research and networking which has achieved outstanding results and impacts. This highlights the role of JPIAMR as a key initiative helping to understand and curb AMR on a global scale.

JPIAMR is leading the development of the One Health AMR Partnership within the Horizon Europe Framework Programme. We look forward to working together with members to seek and support solutions to curb AMR.

“It is impressive to see what JPIAMR members have made possible during these ten years. The results from funded research are astonishing and important, showing that the JPIAMR model works. JPIAMR is well suited to lead the development of the One Health AMR Partnership. We can only imagine what will be achieved in the ten years to come. I am joining all of the members and the AMR research community in wishing JPIAMR a Happy Birthday!” – Jan-Ingvar Jönsson, JPIAMR Chair

See highlights from JPIAMR’s ten year history in the folder “JPIAMR Ten years of achievements” (pdf 0,5 MB)

Call picture

Pre-announcement: Research call on drug resistance

We are pleased to pre-announce the transnational project call Disrupting drug resistance using innovative design under the umbrella of the JPIAMR. The call will involve 26 funding organisations from 17 countries and the total estimated call budget is about 17 million Euro.

This call aims to improve the treatment of bacterial and fungal infections (including co-infection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

The call opens on 11 January 2022.

Read more on the Disrupting drug resistance using innovative design call page.

Diagnostics and Surveillance Networks call image

Pre-announcement: Diagnostics and surveillance network call

JPIAMR is launching the call Diagnostics and Surveillance Networks in April 2022 with the aim to assemble networks of leading experts and stakeholders with an intent to facilitate the development, optimisation and use of diagnostic and surveillance tools, technologies and systems.

Eleven (11) JPIAMR-ACTION members are participating in this network call to date. Each network coordinator will be able to apply for a maximum of 50,000 Euro for 12 or 24 months period for support of its activities.

Read more on the Diagnostics and Surveillance Networks call page.

JPIAMR awards new projects in the area of transmission and interventions

Nineteen projects involving 114 partners from 35 different countries have been recommended for funding within the JPIAMR 13th transnational call One Health interventions to prevent or reduce the development and transmission of antimicrobial resistance. The total funding amount is 25,6 M€.

The call, launched in January 2021, was within the framework of the ERA-NET JPIAMR-ACTION and supported by 30 research funding organisations from 21 countries and by the European Commission. Using a One Health approach, the call aimed to understand the impact of interventions on the development and transmission of antibiotic resistance and to design, implement, evaluate, and compare interventions reducing the development and transmission of antibiotic resistance. Applicants were encouraged to consider the use of interventions that may have an impact in areas where the risk and burden of AMR is greatest, such as in Low and Middle Income countries.

The projects recommended for funding are:

Workshop Report – Interventions to Reduce the Development and Transmission of AMR

We are happy to share the report of the recent online workshop entitled “Interventions to Reduce the Development and Transmission of AMR”. The workshop was hosted by The French National Research Agency (ANR), in close colla

We are happy to share the report of the recent online workshop hosted by The French National Research Agency (ANR).

We are happy to share the report of the recent online workshop entitled “Interventions to Reduce the Development and Transmission of AMR”. The workshop was hosted by The French National Research Agency (ANR), in close collaboration with JPIAMR. Please find the full report here.

Trailer – Overview of AMR science policy and funding

JPIAMRs Laura Marin presents the article published in the journal Trends in Microbiology on AMR, science policy, innovation, public health and funding. The article summarises the many recent AMR projects (JPIAMR, TATFAR, CARB-X, GARDP, ND4BB , G7/ G20 Health Ministers, and more) and is a good general reference and entry to the AMR community. The article is co-authored by Arjon Van Hengel (Directorate-General for Research & Innovation, European Commission) and Laura Marin (JPIAMR).

 

Pre-announcement: Call on AMR Diagnostics and Surveillance

JPIAMR is pleased to pre-announce a joint transnational research call for proposals for innovative research projects on new or improved diagnostic and surveillance strategies, tools, technologies and methods.  The call will support research projects that also have the potential for impact in areas where the risk and burden of AMR is greatest, such as in LMIC settings in Asia and Africa. Projects are encouraged to use a One Health approach where relevant.

The projected call budget is approx. 20 million Euro.

To read more about the call, please click here.

Report – Countries Should Increase Funding for AMR Research by 50%

Today we are reached by the final report from DRIVE-AB with the headline: “Revitalizing the Antibiotic Pipeline“. The context is that “The current pipeline for innovative antibiotics in various stages of R&D is insufficient, potentially delivering no more than one innovative antibiotic for a “critical” World Health Organization (WHO) priority pathogen within the next five years.”, the report say in the beginning.  A key reason for the DRIVE-AB report is to bring recommendations and guidance in the present context, when we are facing increased antibiotic resistance on a global scale.

One of the main recommendations is that countries should increase funding for AMR.

“Countries should make long-term commitments to continue financing of antibacterial R&D and ideally increase push funding by about 50 per cent.”, states the report.

DRIVE-AB finds that: “There may be capacity within existing multinational grant funding agencies – e.g. CARB-X, GARDP, JPIAMR (Joint Programming Initiative on Antimicrobial Resistance) – to absorb and effectively deploy more capital.”

So, we are happy to see that JPIAMR is acknowledged as a key organisation and vehicle, among others,  who are trusted with the mission to fund even more research in order to harness AMR on a global scale. Since JPIAMR is coordinating research and funding for it’s 26 member nations – it fits very well to expand the operations in this direction.

The Drive-AB report continues: “Owing to the existing pipeline, much of this immediate funding should be placed in early- and mid-stage grants until the pipeline becomes more robust. Granting agencies should have specific calls for research targeting pathogens that pose the most urgent public health threats (e.g. WHO’s priority pathogens list for the discovery phase and TPPs for the development phase).”

The ongoing JPIAMR call for “New targets, compounds and tools – innovating against antibiotic resistant bacteria“, is a perfect example how countries are pooling resources and research to collaborate. This call responds to WHOs list of priority pathogens just as the report recommends.

However, funding is linked with the ability to both reach and enable researcher to apply for funds. This is something many more entities in the AMR field could collaborate on to a greater extent. If researchers are not aware of available funds and contexts to support research, we may miss opportunities to support research that can be life changing for the many.